We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+32.82%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.14B
AUM Growth
+$551M
Cap. Flow
+$421M
Cap. Flow %
37.05%
Top 10 Hldgs %
39.86%
Holding
141
New
51
Increased
36
Reduced
11
Closed
41

Top Buys

Rank Stock Value
1
VRAY
ViewRay, Inc.
VRAY
+$18.2M
2
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$10.6M
3
IMDX
Insight Molecular Diagnostics
IMDX
+$10.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.48M
5
SRACU
Stable Road Acquisition Corp. Unit
SRACU
+$4.41M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$11.1M
2
GILD icon
Gilead Sciences
GILD
+$9.51M
3
SNN icon
Smith & Nephew
SNN
+$8.66M
4
BAX icon
Baxter International
BAX
+$4.96M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.45M

Sector Composition

Rank Sector Weight
1 Healthcare 26.48%
2 Industrials 0.92%
3 Consumer Staples 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITCI
126
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-109,130
Closed -$815K
DCPH
127
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-41,000
Closed -$1.39M
MRTX
128
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-50,000
Closed -$3.9M
SPPI
129
PUT
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-500,000
Closed -$4.15M
VRAY
130
CALL
DELISTED
ViewRay, Inc.
VRAY
– –
-2,250,000
Closed -$6.53M
IVC
131
CALL
DELISTED
Invacare Corporation
IVC
– –
-400,000
Closed -$3M
ENDP
132
CALL
DELISTED
Endo International plc
ENDP
– –
-200,000
Closed -$642K
MSON
133
DELISTED
Misonix Inc
MSON
– –
-93,645
Closed -$1.88M
CMD
134
PUT
DELISTED
Cantel Medical Corporation
CMD
– –
-25,000
Closed -$1.87M
GWPH
135
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-30,000
Closed -$3.45M
WMGI
136
CALL
DELISTED
Wright Medical Group Inc
WMGI
– –
-150,000
Closed -$3.1M
STML
137
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-132,422
Closed -$1.38M
ACHN
138
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-566,600
Closed -$2.04M
MDCO
139
CALL
DELISTED
Medicines Co
MDCO
– –
-100,000
Closed -$5M
BDSI
140
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-515,111
Closed -$2.17M
BHVN
141
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-40,000
Closed -$1.98M
2 3 4 5
6

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2019 Portfolio in Review

As of Q4 2019, Pura Vida Investments held 141 positions worth $1.14B, up 94% from $585M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Pura Vida Investments deployed $421M of net new capital in Q4 2019, opening 51 new positions and adding to 36 existing holdings. Its largest new stake was Insight Molecular Diagnostics: 284,829 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 40% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Establishment Labs, an estimated $1.39M trimmed.

  • Pura Vida Investments's largest Q4 2019 buy was Insight Molecular Diagnostics: 284,829 shares worth $12.8M.
  • Pura Vida Investments added most to ViewRay, Inc. in Q4 2019, an estimated $18.2M increase.
  • Pura Vida Investments's biggest Q4 2019 reduction was Establishment Labs, cutting an estimated $1.39M.
  • Pura Vida Investments fully exited Regeneron Pharmaceuticals in Q4 2019, selling an estimated $11.1M.
  • Pura Vida Investments's ten largest holdings make up 40% of its $1.14B portfolio in Q4 2019.
  • Pura Vida Investments opened 51 new positions and closed 41 in Q4 2019.
  • Pura Vida Investments's portfolio value rose 94% quarter-over-quarter to $1.14B.

Based on Pura Vida Investments's 13F filing for Q4 2019, filed 14 Feb 2020.